+91-9896593699

DRDEEPAKSHUKLA https://www.cancerinfo.in
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

919896539256

Question- Is it possible to cure CML (CHRONIC MYELOID LEUKEMIA) one of the types of blood cancer with tablets (bcr-abl kinase inhibitor) eg imatinib, nilotinib or dasatinib?Answer- We don’t know the answer yet, but studies are now looking for stoppi

Chronic lymphocytic leukemia (CLL) is a type of blood cancer common in elderly and may not require treatment immediately after diagnosis as even early treatment does not cure the disease and even without treatment patients survive many years.Treatm

Cancer treatment is complex and requires a team of cancer specialist. It is important to keep in mind that cancer is not a single disease and there are about 200 different types of cancer, to add to the complexity each is staged differently and subse

SCREENING MAMMOGRAPHY - A UNDERUTILISED TOOL AGAINST BREAST CANCER IN INDIAIndian context of breast cancer:Breast cancer is the most common cancer diagnosed in india, close 1.5 lakh new cases are diagnosed each year.It Constitutes around 10% of

Liquid biopsy in non small cell lung cancer is now being used for detection of EGFR mutation analysis in patients who do not have accessible tissue for conventional testing and based on the platform used for liquid biopsy ie digital v/s nondigital it

Soon in india 2 different CDK 4/6 inhibitors will be available thus widening treatment options for hormone positive metastatic breast cancer.CDK 4/6 inhibitors are new class of drugs recently approved for metastatic hormone positive breast cancer

Targeted therapy with gefitinib or erlotinib for 2 years is better than chemotherapy as adjuvant in resected non small cell lung cancer stage l to llla with EGFR mutation. The result suggest better disease free survival, however overall survival data

Double refractory Multiple myeloma is defined as disease resistant to both bortezomib and lenalidomide. It is particularly difficult phase of the disease to treat with median survival of 8-9 months and limited treatment options. But scenario has

services